Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
100mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
ln Vitro |
iGOT1-01's IC50 in the GOT1/MDH1 test was 84.6 μM. iGOT1-01 did not exhibit any inhibitory action on MDH1 by itself at a dose of 100 μM [2]. iGOT1-01 demonstrated minimal harm in two cell viability measurements using PaTu8902 pancreatic cancer cells and DLD1 colon cancer cells (3.125-200 μM; for 3 hours).
|
---|---|
ln Vivo |
iGOT1-01 (Compound 1a; 20 mg/kg; oral) has reasonable bioavailability and exposure characteristics (t1/2=0.7 hours, Cmax=4133 ng/mL, AUC (0-24 hours)=11734 hours·ng /mL) [1].
|
Animal Protocol |
Animal/Disease Models: 9weeks old female CD1 mice [1]
Doses: 20 mg/kg (pharmacokinetic/PK/PK analysis) Route of Administration: Oral Experimental Results: Reasonable bioavailability and exposure characteristics (t1/2=0.7 hrs (hrs (hours)), Cmax=4133 ng/mL, AUC (0-24 hrs (hrs (hours)))=11734 hrs (hrs (hours))·ng/mL). |
References |
[1]. Justin Anglin, et al. Discovery and optimization of aspartate aminotransferase 1 inhibitors to target redox balance in pancreatic ductal adenocarcinoma. Bioorg Med Chem Lett. 2018 Sep 1;28(16):2675-2678.
[2]. Melissa C Holt, et al. Biochemical Characterization and Structure-Based Mutational Analysis Provide Insight into the Binding and Mechanism of Action of Novel Aspartate Aminotransferase Inhibitors. Biochemistry. 2018 Nov 27;57(47):6604-6614. |
Molecular Formula |
C19H20N4O
|
---|---|
Molecular Weight |
320.4
|
Exact Mass |
320.16
|
Elemental Analysis |
C, 71.23; H, 6.29; N, 17.49; O, 4.99
|
CAS # |
882256-55-5
|
Appearance |
Solid powder
|
SMILES |
O=C(N1CCN(C2=CC=CC3=C2C=CN3)CC1)NC4=CC=CC=C4
|
InChi Key |
MGSDOEMLWKEWSV-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C19H20N4O/c24-19(21-15-5-2-1-3-6-15)23-13-11-22(12-14-23)18-8-4-7-17-16(18)9-10-20-17/h1-10,20H,11-14H2,(H,21,24)
|
Chemical Name |
4-(1H-Indol-4-yl)-N-phenylpiperazine-1-carboxamide
|
Synonyms |
iGOT101; iGOT1 01; iGOT1-01; iGOT 101; iGOT-101;
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~312.12 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.80 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.80 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.80 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.1211 mL | 15.6055 mL | 31.2110 mL | |
5 mM | 0.6242 mL | 3.1211 mL | 6.2422 mL | |
10 mM | 0.3121 mL | 1.5605 mL | 3.1211 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.